1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

57−63−6 : 17alpha−Ethinylestradiol 

Concentration (uM)

Efficacy − fraction(E2)

Agonist: Strong

Antagonist: Inactive

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

57−63−6 : 17alpha−Ethinylestradiol 

 Agonist: 1 Antagonist: 0

Concentration (uM)

Receptor Score

Agonist: Strong

Antagonist: Inactive

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

50−28−2 : 17beta−Estradiol 

Concentration (uM)

Efficacy − fraction(E2)

Agonist: Strong

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

50−28−2 : 17beta−Estradiol 

 Agonist: 1 Antagonist: 0

Concentration (uM)

Receptor Score

Agonist: Strong

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

56−53−1 : Diethylstilbestrol 

Concentration (uM)

Efficacy − fraction(E2)

Agonist: Strong

Antagonist: Inactive

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

56−53−1 : Diethylstilbestrol 

 Agonist: 1 Antagonist: 0

Concentration (uM)

Receptor Score

Agonist: Strong

Antagonist: Inactive
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

84−16−2 : meso−Hexestrol 

Concentration (uM)

Efficacy − fraction(E2)

Agonist: Strong

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

84−16−2 : meso−Hexestrol 

 Agonist: 1 Antagonist: 0

Concentration (uM)

Receptor Score

Agonist: Strong

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

57−91−0 : 17alpha−Estradiol 

Concentration (uM)

Efficacy − fraction(E2)

Agonist: Moderate

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

57−91−0 : 17alpha−Estradiol 

 Agonist: 1 Antagonist: 0

Concentration (uM)

Receptor Score

Agonist: Moderate

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

140−66−9 : 4−(1,1,3,3−Tetramethylbutyl)phenol 

Concentration (uM)

Efficacy − fraction(E2)

Agonist: Moderate

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

140−66−9 : 4−(1,1,3,3−Tetramethylbutyl)phenol 

 Agonist: 0.56 Antagonist: 0

Concentration (uM)

Receptor Score

Agonist: Moderate
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

53−16−7 : Estrone 

Concentration (uM)

Efficacy − fraction(E2)

Agonist: Moderate

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

53−16−7 : Estrone 

 Agonist: 0.99 Antagonist: 0

Concentration (uM)

Receptor Score

Agonist: Moderate

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

599−64−4 : 4−Cumylphenol 

Concentration (uM)

Efficacy − fraction(E2)

Agonist: Weak

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

599−64−4 : 4−Cumylphenol 

 Agonist: 0.54 Antagonist: 0

Concentration (uM)

Receptor Score

Agonist: Weak

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

521−18−6 : 5alpha−Dihydrotestosterone 

Concentration (uM)

Efficacy − fraction(E2)

Agonist: Weak

Antagonist: Inactive

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

521−18−6 : 5alpha−Dihydrotestosterone 

 Agonist: 0.5 Antagonist: 0

Concentration (uM)

Receptor Score

Agonist: Weak

Antagonist: Inactive
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

80−05−7 : Bisphenol A 

Concentration (uM)

Efficacy − fraction(E2)

Agonist: Weak

Antagonist: Inactive

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

80−05−7 : Bisphenol A 

 Agonist: 0.65 Antagonist: 0

Concentration (uM)

Receptor Score

Agonist: Weak

Antagonist: Inactive

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

77−40−7 : Bisphenol B 

Concentration (uM)

Efficacy − fraction(E2)

Agonist: Weak

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

77−40−7 : Bisphenol B 

 Agonist: 0.75 Antagonist: 0.0031

Concentration (uM)

Receptor Score

Agonist: Weak

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

486−66−8 : Daidzein 

Concentration (uM)

Efficacy − fraction(E2)

Agonist: Weak

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

486−66−8 : Daidzein 

 Agonist: 0.62 Antagonist: 0

Concentration (uM)

Receptor Score

Agonist: Weak
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

446−72−0 : Genistein 

Concentration (uM)

Efficacy − fraction(E2)

Agonist: Weak

Antagonist: Inactive

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

446−72−0 : Genistein 

 Agonist: 0.77 Antagonist: 0

Concentration (uM)

Receptor Score

Agonist: Weak

Antagonist: Inactive

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

143−50−0 : Kepone 

Concentration (uM)

Efficacy − fraction(E2)

Agonist: Weak

Antagonist: Inactive

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

143−50−0 : Kepone 

 Agonist: 0.23 Antagonist: 0.029

Concentration (uM)

Receptor Score

Agonist: Weak

Antagonist: Inactive

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

789−02−6 : o,p'−DDT 

Concentration (uM)

Efficacy − fraction(E2)

Agonist: Weak

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

789−02−6 : o,p'−DDT 

 Agonist: 0.49 Antagonist: 0

Concentration (uM)

Receptor Score

Agonist: Weak
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

58−18−4 : 17−Methyltestosterone 

Concentration (uM)

Efficacy − fraction(E2)

Agonist: Very Weak

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

58−18−4 : 17−Methyltestosterone 

 Agonist: 0.44 Antagonist: 0

Concentration (uM)

Receptor Score

Agonist: Very Weak

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

520−36−5 : Apigenin 

Concentration (uM)

Efficacy − fraction(E2)

Agonist: Very Weak

Antagonist: Inactive

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

520−36−5 : Apigenin 

 Agonist: 0.43 Antagonist: 0

Concentration (uM)

Receptor Score

Agonist: Very Weak

Antagonist: Inactive

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

85−68−7 : Butyl benzyl phthalate 

Concentration (uM)

Efficacy − fraction(E2)

Agonist: Very Weak

Antagonist: Inactive

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

85−68−7 : Butyl benzyl phthalate 

 Agonist: 0.25 Antagonist: 0.001

Concentration (uM)

Receptor Score

Agonist: Very Weak

Antagonist: Inactive
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

480−40−0 : Chrysin 

Concentration (uM)

Efficacy − fraction(E2)

Agonist: Very Weak

Antagonist: Inactive

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

480−40−0 : Chrysin 

 Agonist: 0.16 Antagonist: 0

Concentration (uM)

Receptor Score

Agonist: Very Weak

Antagonist: Inactive

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

115−32−2 : Dicofol 

Concentration (uM)

Efficacy − fraction(E2)

Agonist: Very Weak

Antagonist: Inactive

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

115−32−2 : Dicofol 

 Agonist: 0 Antagonist: 0.039

Concentration (uM)

Receptor Score

Agonist: Very Weak

Antagonist: Inactive

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

117−81−7 : Di(2−ethylhexyl) phthalate 

Concentration (uM)

Efficacy − fraction(E2)

Agonist: Very Weak

Antagonist: Inactive

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

117−81−7 : Di(2−ethylhexyl) phthalate 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

Agonist: Very Weak

Antagonist: Inactive
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

84−74−2 : Dibutyl phthalate 

Concentration (uM)

Efficacy − fraction(E2)

Agonist: Very Weak

Antagonist: Inactive

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

84−74−2 : Dibutyl phthalate 

 Agonist: 0.041 Antagonist: 0.069

Concentration (uM)

Receptor Score

Agonist: Very Weak

Antagonist: Inactive

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

120−47−8 : Ethylparaben 

Concentration (uM)

Efficacy − fraction(E2)

Agonist: Very Weak

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

120−47−8 : Ethylparaben 

 Agonist: 0.12 Antagonist: 0

Concentration (uM)

Receptor Score

Agonist: Very Weak

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

60168−88−9 : Fenarimol 

Concentration (uM)

Efficacy − fraction(E2)

Agonist: Very Weak

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

60168−88−9 : Fenarimol 

 Agonist: 0.072 Antagonist: 0.0056

Concentration (uM)

Receptor Score

Agonist: Very Weak
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

520−18−3 : Kaempferol 

Concentration (uM)

Efficacy − fraction(E2)

Agonist: Very Weak

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

520−18−3 : Kaempferol 

 Agonist: 0.34 Antagonist: 0

Concentration (uM)

Receptor Score

Agonist: Very Weak

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

72−43−5 : Methoxychlor 

Concentration (uM)

Efficacy − fraction(E2)

Agonist: Very Weak

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

72−43−5 : Methoxychlor 

 Agonist: 0.38 Antagonist: 0

Concentration (uM)

Receptor Score

Agonist: Very Weak

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

72−55−9 : p,p'−DDE 

Concentration (uM)

Efficacy − fraction(E2)

Agonist: Very Weak

Antagonist: Inactive

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

72−55−9 : p,p'−DDE 

 Agonist: 0.11 Antagonist: 0

Concentration (uM)

Receptor Score

Agonist: Very Weak

Antagonist: Inactive
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

104−40−5 : 4−Nonylphenol 

Concentration (uM)

Efficacy − fraction(E2)

Agonist: Very Weak

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

104−40−5 : 4−Nonylphenol 

 Agonist: 0.11 Antagonist: 0

Concentration (uM)

Receptor Score

Agonist: Very Weak

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1912−24−9 : Atrazine 

Concentration (uM)

Efficacy − fraction(E2)

Agonist: Inactive

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

1912−24−9 : Atrazine 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

Agonist: Inactive

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

50−22−6 : Corticosterone 

Concentration (uM)

Efficacy − fraction(E2)

Agonist: Inactive

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

50−22−6 : Corticosterone 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

Agonist: Inactive
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

66−81−9 : Cycloheximide 

Concentration (uM)

Efficacy − fraction(E2)

Agonist: Inactive

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

66−81−9 : Cycloheximide 

 Agonist: 0 Antagonist: 0.12

Concentration (uM)

Receptor Score

Agonist: Inactive

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

13311−84−7 : Flutamide 

Concentration (uM)

Efficacy − fraction(E2)

Agonist: Inactive

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

13311−84−7 : Flutamide 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

Agonist: Inactive

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

52−86−8 : Haloperidol 

Concentration (uM)

Efficacy − fraction(E2)

Agonist: Inactive

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

52−86−8 : Haloperidol 

 Agonist: 0.011 Antagonist: 0

Concentration (uM)

Receptor Score

Agonist: Inactive
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

52806−53−8 : Hydroxyflutamide 

Concentration (uM)

Efficacy − fraction(E2)

Agonist: Inactive

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

52806−53−8 : Hydroxyflutamide 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

Agonist: Inactive

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

65277−42−1 : Ketoconazole 

Concentration (uM)

Efficacy − fraction(E2)

Agonist: Inactive

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

65277−42−1 : Ketoconazole 

 Agonist: 0 Antagonist: 0.013

Concentration (uM)

Receptor Score

Agonist: Inactive

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

330−55−2 : Linuron 

Concentration (uM)

Efficacy − fraction(E2)

Agonist: Inactive

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

330−55−2 : Linuron 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

Agonist: Inactive
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

57−30−7 : Phenobarbital sodium 

Concentration (uM)

Efficacy − fraction(E2)

Agonist: Inactive

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

57−30−7 : Phenobarbital sodium 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

Agonist: Inactive

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

32809−16−8 : Procymidone 

Concentration (uM)

Efficacy − fraction(E2)

Agonist: Inactive

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

32809−16−8 : Procymidone 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

Agonist: Inactive

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

50−55−5 : Reserpine 

Concentration (uM)

Efficacy − fraction(E2)

Agonist: Inactive

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

50−55−5 : Reserpine 

 Agonist: 0 Antagonist: 8.2e−09

Concentration (uM)

Receptor Score

Agonist: Inactive
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

52−01−7 : Spironolactone 

Concentration (uM)

Efficacy − fraction(E2)

Agonist: Inactive

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

52−01−7 : Spironolactone 

 Agonist: 0 Antagonist: 0

Concentration (uM)

Receptor Score

Agonist: Inactive

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

68392−35−8 : 4−Hydroxytamoxifen 

Concentration (uM)

Efficacy − fraction(E2)

Antagonist: Active

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

68392−35−8 : 4−Hydroxytamoxifen 

 Agonist: 0.0032 Antagonist: 0.96

Concentration (uM)

Receptor Score

Antagonist: Active

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

82640−04−8 : Raloxifene hydrochloride 

Concentration (uM)

Efficacy − fraction(E2)

Antagonist: Active

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

82640−04−8 : Raloxifene hydrochloride 

 Agonist: 0 Antagonist: 0.97

Concentration (uM)

Receptor Score

Antagonist: Active
1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

10540−29−1 : Tamoxifen 

Concentration (uM)

Efficacy − fraction(E2)

Antagonist: Active

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

10540−29−1 : Tamoxifen 

 Agonist: 0.042 Antagonist: 0.69

Concentration (uM)

Receptor Score

Antagonist: Active

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

54965−24−1 : Tamoxifen citrate 

Concentration (uM)

Efficacy − fraction(E2)

Antagonist: Active

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

54965−24−1 : Tamoxifen citrate 

 Agonist: 0.019 Antagonist: 0.78

Concentration (uM)

Receptor Score

Antagonist: Active

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

57−83−0 : Progesterone 

Concentration (uM)

Efficacy − fraction(E2)

Antagonist: Inactive

1e−02 1e−01 1e+00 1e+01 1e+02

0.0 0.2 0.4 0.6 0.8 1.0

57−83−0 : Progesterone 

 Agonist: 0.073 Antagonist: 0

Concentration (uM)

Receptor Score

Antagonist: Inactive